• Recruiting

NCT02693535: Phase 2: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs

Updated: May 19

NCT02693535: Phase 2: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)


tapur


TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)



The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug


Sponsor:

American Society of Clinical Oncology


Collaborators:

AstraZeneca

Bayer

Bristol-Myers Squibb

Eli Lilly and Company

Genentech, Inc.

Merck Sharp & Dohme Corp.

Pfizer

Boehringer Ingelheim

Seagen Inc.


Multiple Locations


 

ClinicalTrials.gov Identifier: NCT02693535


Official Title: Targeted Agent and Profiling Utilization Registry (TAPUR) Study

First Posted : February 26, 2016


https://clinicaltrials.gov/ct2/show/NCT02693535

 

Drug: Crizotinib

Drug: Palbociclib

Drug: Sunitinib

Drug: Temsirolimus

Drug: Trastuzumab and Pertuzumab

Drug: Vemurafenib and Cobimetinib

Drug: RegorafenibDrug: Olaparib

Drug: Pembrolizumab

Drug: Nivolumab and Ipilimumab

Drug: Abemaciclib

Drug: Afatinib

Drug: Talazoparib

Drug: Atezolizumab and PHESGO

Drug: Atezolizumab and Talazoparib

Drug: Entrectinib

Drug: Larotrectinib

Drug: Tucatinib plus Trastuzumab Subcutaneous (SC)

 









Posts Archive